<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Eosinophilic <z:hpo ids='HP_0002090'>pneumonia</z:hpo> is characterized by cough, lung infiltrates on imaging, and by the presence of eosinophils in the alveoli and pulmonary interstitium </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi>, a pyramidine <z:chebi fb="0" ids="33838">nucleoside</z:chebi> analog of <z:chebi fb="0" ids="17562">cytidine</z:chebi>, is FDA approved for the treatment of various <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We present a case of a 76-year-old man with recently diagnosed <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, who developed eosinophilic <z:hpo ids='HP_0002090'>pneumonia</z:hpo> after initiating therapy with <z:chebi fb="0" ids="2038">azacitidine</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>There was clinical and radiographic improvement with cessation of the drug and treatment with <z:chebi fb="0" ids="8382">prednisone</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Diagnosis of drug-induced eosinophilic <z:hpo ids='HP_0002090'>pneumonia</z:hpo> is established by having a temporal relationship between <z:hpo ids='HP_0003674'>onset</z:hpo> of symptoms and initiation of therapy, bronchoalveolar lavage or lung biopsy evidence of pulmonary <z:hpo ids='HP_0001880'>eosinophilia</z:hpo>, no other explanation for the disease, and improvement upon cessation of the offending agent </plain></SENT>
<SENT sid="5" pm="."><plain>Our case illustrates the need for a high index of suspicion to identify adverse pulmonary reactions associated with newly developed medications </plain></SENT>
</text></document>